Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

Company Overview - Annexon, Inc. is a biopharmaceutical company focused on developing novel therapies for classical complement-mediated neuroinflammatory diseases affecting the body, brain, and eye [1][3] - The company targets C1q, a key molecule in the classical complement pathway, to prevent tissue damage and neuroinflammation [3] - Annexon's pipeline includes investigational drug candidates across autoimmune, neurodegenerative, and ophthalmic diseases, addressing the needs of over 8 million people globally [3] Upcoming Events - Douglas Love, the president and CEO of Annexon, will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 8:10 a.m. EST [1] - A live webcast of the presentation will be available on the company's Investors page, with a replay accessible for 30 days post-event [2]